Laboratorios Farmaceuticos Rovi SA (STU:41L) Stock Price, Trades & News

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	0.24
Equity-to-Asset	0.69
Debt-to-Equity	0.2
Debt-to-EBITDA	0.37
Interest Coverage	79.34
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	9.58	Distress Grey Safe
Beneish M-Score	-2.43	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.4
	3-Year EBITDA Growth Rate	3.2
	3-Year EPS without NRI Growth Rate	-0.8
	3-Year FCF Growth Rate	-8.8
	3-Year Book Growth Rate	9.2
	Future 3-5Y EPS without NRI Growth Rate Estimate	19.47
	Future 3-5Y Total Revenue Growth Rate Estimate	8.91

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	24.18
	9-Day RSI	31.75
	14-Day RSI	34.66
	3-1 Month Momentum %	-15.22
	6-1 Month Momentum %	-24.21
	12-1 Month Momentum %	-32.25

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.13
	Quick Ratio	1.02
	Cash Ratio	0.17
	Days Inventory	348.91
	Days Sales Outstanding	53.08
	Days Payable	103.41

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.25
	Dividend Payout Ratio	0.27
	3-Year Dividend Growth Rate	42.6
	Forward Dividend Yield %	2.25
	5-Year Yield-on-Cost %	39.42
	3-Year Average Share Buyback Ratio	2.3
	Shareholder Yield %	2.36

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	64.23
	Operating Margin %	27
	Net Margin %	20.62
	FCF Margin %	7.61
	ROE %	38.79
	ROA %	24.85
	ROIC %	31.59
	3-Year ROIIC %	-8.07
	ROC (Joel Greenblatt) %	47.4
	ROCE %	43.56
	Years of Profitability over Past 10-Year	10

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	12.17
	Forward PE Ratio	19.07
	PE Ratio without NRI	12.18
	Shiller PE Ratio	24.74
	Price-to-Owner-Earnings	12.45
	PEG Ratio	0.37
	PS Ratio	2.51
	PB Ratio	4.38
	Price-to-Tangible-Book	4.66
	Price-to-Free-Cash-Flow	32.98
	Price-to-Operating-Cash-Flow	18.14
	EV-to-EBIT	9.63
	EV-to-EBITDA	8.52
	EV-to-Revenue	2.61
	EV-to-FCF	34.25
	Price-to-GF-Value	0.79
	Price-to-Projected-FCF	1.84
	Price-to-DCF (Earnings Based)	0.35
	Price-to-DCF (FCF Based)	2.64
	Price-to-Median-PS-Value	0.8
	Price-to-Peter-Lynch-Fair-Value	0.49
	Price-to-Graham-Number	1.59
	Price-to-Net-Current-Asset-Value	10.92
	Earnings Yield (Greenblatt) %	10.38
	FCF Yield %	3.03
	Forward Rate of Return (Yacktman) %	23.06

GF Value: €62.01

STU:41L

Warning Signs

Warning! GuruFocus detected 1 Medium warning sign with 41L. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.